Sensorion Reveals Achievement of Main Goal in Phase 2a Trial of SENS-401 for Preserving Remaining Hearing Function.

On March 6th, Nature Reviews Drug Discovery highlighted recent bispecific antibodies (bsAbs) progress in cancer therapy.

Celltrion USA has finalized their application for a biologic license to the U.S. Food and Drug Administration for CT-P39, their alternative biosimilar to XOLAIR (omalizumab).

Phenazopyridine, a diminutive molecule, serves primarily as an analgesic agent for urinary tract pain.

Wegovy® receives green light in the USA to diminish heart-related health hazards for those excessively heavy or with obesity coupled with confirmed heart conditions.

In investigating obesity treatment, the GLP-1 receptor, key for managing Type 2 diabetes and heart disease, is a major focus.

BeiGene, Ltd., a global oncology-focused biopharma, announced FDA's fast-track approval for its cancer drug BRUKINSA(zanubrutinib).

Sodium bicarbonate, approved for medical use since 1981, continues to be a versatile treatment for many conditions.

Eli Lilly and Company announced that the FDA will convene its Advisory Committee to discuss Phase 3 results of the TRAILBLAZER-ALZ 2 study on the efficacy and safety of donanemab in early Alzheimer's.

In February, Amgen published a study in Nature Metabolism about AMG 133, a novel molecule with potential for treating obesity.

Regor Therapeutics Group has announced the launch of its Phase 2 trial on RGT-075, an oral, highly selective GLP-1 receptor agonist.

Triamcinolone, a synthetic corticosteroid, acts as a potent glucocorticoid receptor agonist, mainly used to treat autoimmune diseases such as psoriasis, lupus, and rheumatoid arthritis.